Saturday 10 October 2026
Export all IDXG data to Excel Powerpack
Interpace Biosciences, Inc.
IDXG
Interpace Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.7 million, down 17.5% from fiscal 2024. In the quarter to June 2026, revenue fell 1.09%, EPS grew 104.1% and free cash flow fell 92.1%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years.
6.00
0.00
0.00%
Follow IDXG
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.06 | 0.07 | 0.04 | 0.21 |
+8 more quarters Free account |
P/S ratio |
0.25 | 0.24 | 0.03 | 0.02 | |
P/FCF ratio |
2.20 | 1.93 | 0.22 | 0.20 | |
P/Operating CF |
92.15 | 30.44 | 0.51 | 0.41 | |
P/B ratio |
0.39 | 0.37 | 0.05 | 0.00 | |
Price to Tangible BV |
0.39 | 0.37 | 0.05 | 0.00 | |
EV/Sales |
0.25 | 0.24 | 0.04 | 0.05 | |
EV/EBITDA |
1.80 | 2.06 | 0.29 | 0.41 | |
EV/Operating CF |
2.06 | 1.81 | 0.24 | 0.45 | |
EV/FCF |
2.24 | 1.98 | 0.28 | 0.57 | |
Quick Ratio |
1.82 | 2.16 | 1.60 | 1.24 | |
Current Ratio |
2.22 | 2.51 | 1.94 | 1.54 | |
Net Debt/EBITDA |
(4.83) | (1.96) | (1.38) | (1.04) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.54 | 1.51 | 1.59 | 3.21 | |
Operating CF/Net income |
0.62 | 0.39 | 0.09 | 2.13 | |
Capex/Depreciation |
(0.24) | (0.63) | (0.16) | (0.52) | |
Research and Development Expense of Revenue |
1.63% | 1.69% | 1.54% | 1.71% | |
Selling, General and Administrative Expense of Revenue |
56.76% | 51.24% | 46.88% | 47.33% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.04% | 0.04% | 0.04% | 0.08% | |
Graham Net Nets |
(0.04) | (0.04) | (1.45) | (4.02) | |
Graham Number |
50.33 | 54.54 | 125.75 | 0.00 | |
Earnings Yield |
1,646.26% | 1,381.25% | 2,260.62% | 481.81% | |
Free Cash Flow Yield |
45.45% | 51.71% | 461.73% | 491.15% | |
Revenue per Share |
1.65 | 1.98 | 10.43 | 9.89 | |
Operating CF per Share |
0.02 | 0.06 | 2.42 | 2.19 | |
Capex per Share |
(0.01) | (0.03) | (0.04) | (0.13) | |
Free Cash Flow per Share |
0.01 | 0.03 | 2.37 | 2.06 | |
Cash per Share |
0.49 | 0.58 | 2.83 | 1.61 | |
Shareholders Equity per Share |
4.20 | 5.07 | 25.27 | (0.34) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.20 | 5.07 | 25.27 | (0.34) | |
Free Cash Flow |
0.04 | 0.14 | 2.10 | 1.82 | |
Working Capital |
6.02 | 6.00 | 4.80 | 3.19 | |
Capital Expenditures |
(0.06) | (0.14) | (0.04) | (0.12) | |
Net Current Asset Value |
(0.34) | (0.36) | (1.57) | (3.20) | |
EV/EBIT |
2.20 | 2.61 | 0.35 | 0.49 | |
Capex to Sales |
0.01 | 0.02 | 0.00 | 0.01 | |
Price to Operating Income |
2.17 | 2.55 | 0.27 | 0.17 | |
| Other line items | |||||
Average Receivables |
6.77 | 7.35 | 7.10 | 6.63 | |
Average Payables |
1.40 | 1.27 | 1.32 | 1.56 | |
Average Assets |
23.44 | 23.95 | 24.32 | 13.04 | |
Average Common Equity |
11.02 | 11.25 | 10.07 | (28.99) |
Columns are period end dates · fundamentals updated 28 Sep 2026